Ro
From$149/mo
Source: Ro pricing page · Checked
Checked · confirm at checkout
PlushCare is best for people seeking nationwide, physician-led weight-management care who can navigate insurance or pharmacy pricing, with the main trade-off that its low membership price excludes visits, labs, and medication.
3.9/5
Source: PlushCare weight-loss program · Checked
Check this: Checked over 30 days ago.
Confirm the price at checkout.
The $19.99 membership does not include physician visits, medication, or required laboratory work.
A GLP-1 prescription and insurance approval are not guaranteed.
PlushCare’s compounded semaglutide and tirzepatide pages are conditional on FDA shortage status, but FDA currently lists both shortages as resolved; compounded drugs are not FDA-approved.
From$149/mo
Source: Ro pricing page · Checked
Checked · confirm at checkout
From$149/mo
Source: Hims weight loss page · Checked
Checked · confirm at checkout
From$199/mo
Source: TrimRx homepage · Checked
Checked · confirm at checkout
Educational content only. Do not use this page as medical advice or as a substitute for a licensed clinician, pharmacist or insurer reviewing your situation.
Sources: PlushCare weight-loss programPlushCare pricing and membership detailsPlushCare GLP-1 programPlushCare semaglutide pagePlushCare compounded tirzepatide pageFDA GLP-1 shortage and compounding policyFDA concerns about unapproved GLP-1 drugsChecked
From $19.99/mo
Source: PlushCare weight-loss programPlushCare is best for people seeking nationwide, physician-led weight-management care who can navigate insurance or pharmacy pricing, with the main trade-off that its low membership price excludes visits, labs, and medication.
Last checked Jul 5, 2026
Price snapshot: From $19.99/mo
PlushCare’s advertised starting price is a membership fee, not an all-inclusive GLP-1 package. The official site lists a 30-day free trial followed by $19.99 per month, or an annual membership costing $149. Membership benefits include appointment booking, care-team messaging, prescription-renewal requests, a prescription discount card, discounted laboratory testing, and memberships for family members. Physician appointments remain separately billable. With insurance, the patient pays the applicable copay or other plan-determined amount; PlushCare says many in-network patients pay $30 or less, but it identifies this only as a common result rather than a guarantee. The published cash price for new members is $129 per visit. Medication and laboratory work are expressly excluded. PlushCare says branded GLP-1 drugs without coverage can cost roughly $1,000 monthly, but actual prices can differ substantially by product, pharmacy, insurance benefits, and manufacturer programs. Follow-up appointments can also add recurring costs. Therefore, $19.99 is an appropriate published monthly starting figure for membership, but it should never be presented as the complete cost of treatment. Patients need an itemized estimate covering membership, expected appointments, labs, and the exact medication before comparing PlushCare with bundled programs.
PlushCare’s current GLP-1 pages emphasize prescriptions selected by a physician rather than one guaranteed product. The site identifies Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) as FDA-approved weight-loss medications. It also discusses Ozempic and Mounjaro, but their FDA-approved indications are for type 2 diabetes, not weight loss; insurers commonly require evidence of that diagnosis before covering them. PlushCare also maintains pages for compounded semaglutide and tirzepatide. Those pages clearly state that compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or manufacturing quality. More importantly, PlushCare says its compounded versions can only be offered through the published shortage pathway while the corresponding brands remain on FDA’s shortage list. FDA currently states that the semaglutide and tirzepatide injection shortages are resolved and that neither substance is presently on its shortage list. Based on PlushCare’s own condition, readers should not assume its displayed compounded prices represent currently purchasable options. The practical model in July 2026 should be treated as FDA-approved brand prescribing, subject to clinician judgment and availability, unless PlushCare documents a lawful patient-specific compounding basis. Any proposed product should be verified by exact name, manufacturer or compounding pharmacy, FDA status, and intended indication.
Pricing ledger
These are the public pricing claims and checkout questions that decide whether the offer is actually comparable.
Thirty-day free trial advertised; $149/year option also listed.
Confirm checkout price, trial expiration, cancellation terms, and whether limited nonmember access is available.PlushCare advertises $129 for cash-pay visits by new members; insured cost depends on benefits.
Confirm the initial and follow-up visit prices with PlushCare and the insurer.FDA-approved brands may use insurance or cash payment; no universal medication price is published.
Confirm the exact drug, indication, coverage, pharmacy, and final price.PlushCare says it is licensed nationwide, but specific medications and clinicians may not be available everywhere.
Check clinician, pharmacy, and medication availability for the patient’s state.Source: PlushCare weight-loss program · Checked
Checked · confirm at checkout
PlushCare describes a physician-led process delivered through video visits. During the first appointment, a doctor reviews medical history, previous weight-management efforts, current medications, underlying conditions, and treatment goals. The official program page says laboratory work is often required; its GLP-1 page describes an obesity panel that can include blood count, metabolic function, lipids, A1C, thyroid testing, and insulin. The doctor then reviews the results and discusses treatment options during a subsequent visit. A prescription is issued only when the clinician finds it medically appropriate and may be sent to the patient’s selected local pharmacy. PlushCare says its care team can prepare prior-authorization requests for injectable weight-loss and diabetes medications. That administrative help does not ensure approval, and the insurer’s pharmacy-benefit manager makes the coverage decision. PlushCare’s semaglutide page says patients generally meet with their doctor monthly while treatment is being adjusted and lifestyle routines are being developed. Because visits are not included in membership, that cadence can materially affect total cost. Membership includes unlimited messaging with the care team, but it should not be interpreted as unlimited physician consultations. PlushCare says it is fully licensed to provide care in all 50 states, while also warning that not every FDA-approved medication is available in every location.
The $19.99 membership does not include physician visits, medication, or required laboratory work.
Before enrolling, request a written estimate separating membership, initial consultation, anticipated follow-ups, laboratory charges, and medication. Confirm when the 30-day trial ends, how cancellation works, and whether PlushCare’s limited-access option without a paid membership can be used for weight-management care. Patients using insurance should verify that PlushCare and the selected physician are in network, then contact the pharmacy-benefit manager about the exact drug and diagnosis. Questions should cover formulary status, prior authorization, step therapy, deductibles, copays, and whether weight-loss medication is excluded altogether. PlushCare can submit prior-authorization documentation, but coverage remains uncertain until the insurer issues a decision. For cash purchases, obtain the current price from the dispensing pharmacy or manufacturer program rather than relying on PlushCare’s approximate brand-cost statement. If a compounded product is proposed, ask for the pharmacy’s legal name, state license, 503A or 503B status, formulation, and the documented reason compounding is permissible despite resolved national shortages. Verify that information against FDA’s current shortage and compounding guidance. PlushCare’s compound pages publish state-specific lists, but those lists do not override the shortage condition and may become outdated. Finally, confirm that the prescription record identifies whether the dispensed item is an FDA-approved manufacturer product or a non-FDA-approved compound.
PlushCare may fit adults who want an ongoing relationship with a primary-care physician, prefer video appointments, and are prepared to use insurance or compare pharmacy options for an FDA-approved medication. Its nationwide care footprint, same-day appointment availability, care-team messaging, and prior-authorization assistance are useful for patients who value clinical access more than a single bundled price. It can also make sense when the patient wants a clinician who can address health issues beyond weight management. It is less suitable for someone seeking a predictable, medication-included subscription. The headline membership price excludes every physician visit, laboratory work, and the medication itself, while monthly follow-ups may be needed during treatment changes. It also does not fit anyone expecting a guaranteed GLP-1 prescription or guaranteed insurance coverage: the clinician may recommend lifestyle support, a non-GLP-1 medication, or no prescription, and the insurer may deny authorization. People who want only an FDA-approved brand should confirm the exact product before paying. Those specifically shopping for inexpensive compounded semaglutide or tirzepatide should be especially cautious because PlushCare’s published offer is conditional on national shortages that FDA currently considers resolved. Overall value depends on the patient’s insurance benefits, follow-up frequency, required labs, and final pharmacy price—not on the membership fee alone.
Side-by-side
Use this as a shortlist, not a final ranking. The right choice still depends on your quote, medication route, insurance result and follow-up needs. All comparison pages.
| Provider | Advertised cost | Medication path |
|---|---|---|
| PlushCareCurrent review · Score 3.9/5 | From $19.99/mo Source: PlushCare weight-loss program · Checked Checked · confirm at checkout | Brand meds billed separately |
| TrimRxScore 4.1/5 | From $199/mo Source: TrimRx homepage · Checked Checked · confirm at checkout | Compounded GLP-1 |
| Hims + HersScore 4.2/5 | From $149/mo meds + membership Source: Hims weight loss page · Checked Checked · confirm at checkout | FDA-approved brand paths |
| RoScore 4.3/5 | $39 first month; meds separate Source: Ro pricing page · Checked Checked · confirm at checkout | Brand GLP-1 + insurance support |
Educational content only. Do not use this page as medical advice or as a substitute for a licensed clinician, pharmacist or insurer reviewing your situation.
Sources
Official program workflow, eligibility language, membership and visit pricing, medication-cost exclusions, and insurance information.
Official monthly and annual membership prices, visit charges, membership benefits, limited-access disclosure, and all-50-state statement.
Official lists of weight-loss and diabetes medications, laboratory process, location caveat, and prior-authorization workflow.
Official brand-versus-compound distinction, conditional compound pricing and states, clinician workflow, and monthly follow-up description.
Official non-FDA-approved disclosure, conditional state availability, displayed medication-only prices, and shortage requirement.
FDA states that the semaglutide and tirzepatide shortages are resolved and neither currently appears on its shortage list.
FDA explanation that compounded GLP-1 drugs are not approved and do not undergo premarket review for safety, effectiveness, and quality.